. 2022 Apr 7;6:24. doi: 10.1038/s41698-022-00263-x

Table 2.

Selected Studies of PET Tracers of CD8, PD-1 and PD-L1 in Human Clinical Trials.

	Molecule	Trial Details
PD-1
	⁸⁹Zr-DFO-Nivolumab	13 patient study in advanced NSCLC. Dual tracer study with ¹⁸F-BMS-986192. IHC PD-1 and PD-L1 staining and SUVpeak for ⁸⁹Zr-nivolumab and ¹⁸F-BMS- 986192 is strongly correlated (Rs = 0.68, p < 0.0001 Spearman rank correlation). Lesions with no PD-1 expression in aggregates have a lower ⁸⁹Zr-nivolumab SUVpeak; p = 0.03¹¹⁶.
	⁸⁹Zr-DFO-Pembrolizumab	12 patients in advanced NSCLC. Tracer seen in 47% of tumour lesions correlated with pembrolizumab response, but did not correlate with PD-L1 or PD1 IHC¹⁹³.
PD-L1
	⁸⁹Zr-DFO-Atezolizumab	FTIH 25 patient study. Pretreatment atezolizumab-PET better correlated with Immunotherapy response than IHC or RNA-seq markers¹⁷.
	¹⁸F-BMS-986192	¹⁸F-BMS-986192 SUVpeak is higher in patients with ≥50% tumor PD-L1 expression. (p = 0.018), SUVpeak of the ¹⁸F-BMS-986192 tracer is higher in responding lesions as compared to non-responding lesions (p = 0.02 Mann–Whitney U-test).
	⁸⁹Zr-DFO-Durvalumab	RaDD Study - currently recruiting²¹. ⁸⁹Zr-durva PET during chemo/RT for DLBCL. Trial Registration ClinicalTrials. gov Identifier: NCT03107663¹⁹⁴. No significant toxicity reported in >18 patients. NKI 13 patient study in patients eligible for 2nd line ICI. ⁸⁹Zr-durva correlated with disease response but not PD-L1 IHC¹⁸.
	⁸⁹Zr-DFO-Sq-Durvalumab	ImmunoPET study – currently recruiting. ⁸⁹Zr-durva during concurrent chemoRT in Stage III NSCLC. Australian Clinical Trial Registry: ACTRN12621000171819¹⁹⁵.
CD8 T-cells
CD8 T-cells	⁸⁹Zr-DFO-IAB22M2C minibody	FTIH 6 patient study: uptake in tumour lesions peaked at 24 h²¹. Ph II (mixed histology) 15 patient study – increased tracer uptake noted in patients 28 days post-immunotherapy²². RaDD study in B Cell lymphomas now recruiting¹⁹⁴. No significant toxicity yet documented.
Activated T-cells
Activated T-cells	¹⁸F-AraG (Arabinofuranosylguanine)	FTIH 6 patient study with no significant adverse events seen^21,23. Ongoing studies in 18 patients with no drug related adverse events. (Unpublished data supplied by Cellsight Technologies).